PMV Pharmaceuticals (PMVP) Form 3 PMV Pharmaceuticals / Michael Carulli ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Carulli Michael

(Last) (First) (Middle)

C/O PMV PHARMACEUTICALS, INC.

ONE RESEARCH WAY

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/05/2024

3. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	9,066(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	(2)	06/02/2030	Common Stock	24,632	4.22	D
Employee Stock Option (right to buy)	(3)	05/12/2031	Common Stock	13,605	28.33	D
Employee Stock Option (right to buy)	(4)	02/10/2032	Common Stock	27,200	16.29	D
Employee Stock Option (right to buy)	(5)	05/12/2033	Common Stock	75,000	5.7	D

Explanation of Responses:

1. The shares are represented by restricted stock units which vest on September 9, 2024.

2. An option to purchase 28,489 shares was granted on June 2, 2020 and was exercised in part prior to the date on which the reporting person became subject to Section 16. One-fourth of the shares subject to the option vested on May 26, 2021, and the remaining shares vest in 36 equal monthly installments beginning on June 26, 2021.

3. Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021.

4. Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022.

5. Shares subject to the option vest in 48 equal monthly installments beginning on June 12. 2023.

Remarks:

	/s/ Robert Ticktin, by power of attorney	01/11/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.